Recovery Or Purification Patents (Class 435/239)
-
Publication number: 20090123988Abstract: The invention relates to a method for the specific or non-specific separation of cells and/or viruses from liquid media which is based on adsorption of the species on a correspondingly functionalised carrier material. The method according to the invention is used for separation and also isolation of any species of cells and viruses.Type: ApplicationFiled: January 9, 2006Publication date: May 14, 2009Applicants: Hansastrasse 27 c,, Fraunhofer Geseilschaft zur Forderung der Angewandten Forschung E.V.Inventors: Andreas Holländer, Michael Keusgen, Johannes Kramer, Ansgar Ferner
-
Publication number: 20090123989Abstract: The invention provides a method for the purification, of a virus comprising a step of ultrafiltration wherein the reteniate contains the virus, wherein back pressure of at least 5 kPa is applied on the permeate side.Type: ApplicationFiled: April 11, 2006Publication date: May 14, 2009Applicant: CRUCELL HOLLAND B.V.Inventor: Miranda Weggeman
-
Patent number: 7527961Abstract: Means and methods for producing mammalian viruses, the method comprising infecting a culture of immortalized human cells with a virus, incubating the culture infected with virus to propagate the virus under conditions that permit growth of the virus, and to form a virus-containing medium, and removing the virus-containing medium. The viruses can be harvested and be used for the production of vaccines. Advantages include that human cells of the present invention can be cultured under defined serum-free conditions and the cells show improved capability for propagating virus. Methods are provided for producing, in cultured human cells, influenza virus and vaccines derived thereof. This method eliminates the necessity of using whole chicken embryos for the production of Influenza vaccines. The method also provides for the continuous or batch-wise removal of culture media. As such, the present invention allows the large-scale continuous production of viruses to a high titer.Type: GrantFiled: November 11, 2005Date of Patent: May 5, 2009Assignee: Crucell Holland B.V.Inventors: Maria Grazia Pau, Alphonsus G. C. M. UytdeHaag, Govert Johan Schouten
-
Patent number: 7524676Abstract: The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.Type: GrantFiled: March 17, 2005Date of Patent: April 28, 2009Assignee: Baxter Healthcare S.A.Inventors: Manfred Reiter, Wolfgang Mundt
-
Patent number: 7521219Abstract: The present invention is directed to a method for producing commercial quantities of baculovirus using a combination of methods involving producing occlusion bodies with infectious baculovirus in caterpillar larvae and large numbers of viral particles with serial passages in cell culture. A two step method was developed by initially producing infectious virus in caterpillar larvae and then using the resultant infectious virus as an inoculum for a limited number of serial passages in cell culture so to produce large amounts of infectious baculovirus.Type: GrantFiled: November 10, 2004Date of Patent: April 21, 2009Assignee: The University of QueenslandInventors: Steven Reid, Linda Lua
-
Patent number: 7521201Abstract: Compositions containing bacteriophages and methods of using bacteriophages in microorganism detection assays and microbial growth and plating media are disclosed. The lytic ability of these phages to control the growth of non-target populations provides superior sensitivity and specificity to detection assays and reduces false negative and false positive results. The removal of contaminating bacteria reduces the microbial competition for nutrients in the growth media thereby increasing the efficiency and productivity of the culture. The phage treatment of the sample increases the proportion of target microorganisms in the sample over contaminating bacteria thereby requiring less time for enrichment to obtain a significant signal improving overall signal to noise ratio in assays and providing for higher yield of end product in microbiological production systems.Type: GrantFiled: October 31, 2005Date of Patent: April 21, 2009Assignee: Strategic Diagnostics Inc.Inventors: James W. Stave, George B. Teaney, III
-
Publication number: 20090092620Abstract: The invention relates to a flu virus hemagglutinin-specific monoclonal antibody which recognizes an antigenic structure present both on the H1 and H3 subtypes of the hemagglutinins of type A flu viruses and on the hemagglutinin of type B flu viruses. Within type B flu viruses, the antigenic structure is present on the hemagglutinins of type B flu viruses belonging to the B/Victoria group and/or to the B/Yagamata group.Type: ApplicationFiled: October 7, 2008Publication date: April 9, 2009Applicant: SANOFI PASTEURInventors: Catherine Moste, Isabelle Legastelois, Michel Chevalier, Laurent Thion
-
Patent number: 7510872Abstract: The present invention relates to methods and materials for recombinant adeno-associated virus production. More particularly, the invention relates to use of recombinant adenovirus encoding adeno-associated virus protein in recombinant adeno-associated virus production methods.Type: GrantFiled: February 26, 2004Date of Patent: March 31, 2009Assignee: Nationwide Children's HospitalInventors: Kelly Reed Clark, Philip Rudolph Johnson, Jr.
-
Patent number: 7510862Abstract: Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as “MERV-env”, “MERV-gag”, “MERV-prt” and “MERV-pol” at the DSMZ on 26 Sep. 2001 or fragments thereof.Type: GrantFiled: September 27, 2002Date of Patent: March 31, 2009Assignee: Avir Green Hills Biotechnology Research Development Trade AGInventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
-
Publication number: 20090081173Abstract: Disclosed are methods of increasing the virulence of a bacteriophage, comprising contacting a bacteriophage with a composition comprising a bacterium or bacterial extract; and a polymer. Also disclosed are methods of propagating and isolating therapeutic bacteriophages that involve use of dilute polymer compositions. Also disclosed are pharmaceutical compositions the bacteriophage for which virulence has been increased by the methods set forth herein or which have been isolated by the methods set forth herein.Type: ApplicationFiled: August 8, 2008Publication date: March 26, 2009Inventor: Philip Serwer
-
Patent number: 7504109Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: May 20, 2005Date of Patent: March 17, 2009Assignees: MedImmune, LLC, The United States of America as Represented by The Department of Health Services, National Institute of HealthInventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
-
Patent number: 7494813Abstract: The invention relates to a VAC-BAC shuttle vector system for creation of recombinant poxviruses from DNA cloned in a bacterial artificial chromosome.Type: GrantFiled: October 5, 2004Date of Patent: February 24, 2009Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Bernard Moss, Arban Domi
-
Publication number: 20090042273Abstract: A process of harvesting a herpesvirus from a cell culture infected therewith comprises treating said culture with a hypertonic aqueous salt solution to yield a virus suspension, e.g. to give improved yield of virus for live virus vaccine where otherwise cell-disruption might be used to harvest the virus by disrupting virus-infected cells. The harvesting step can be followed e.g. by nuclease treatment, diafiltration and lyophilisation.Type: ApplicationFiled: September 11, 2008Publication date: February 12, 2009Inventors: Michael Denis Johnston, Roderic Simon O'Keeffe
-
Publication number: 20090042274Abstract: An industrial purification method of a virus (e.g., Hemagglutinating Virus of Japan, HVJ) envelope is provided. To be specific, a method of purifying an inactivated virus envelope at a high recovery rate by ion exchange chromatography and hydrophobic chromatography, while maintaining the cell fusion activity of the virus, is provided. The purified virus envelope can be used as a vector for introducing a biopolymer such as gene and the like into a cell or a living organism. In addition, this method can be used for purification of an attenuated envelope virus.Type: ApplicationFiled: July 22, 2005Publication date: February 12, 2009Applicant: GENOMIDEA INC.Inventor: Shinichi Ioka
-
Publication number: 20090035838Abstract: A microfluidic device for analyzing and/or sorting biological materials (e.g., molecules such as polynucleotides and polypeptides, including proteins and enzymes; viruses and cells) and methods for its use are provided. The device and methods of the invention are useful for sorting particles, e.g. virions. The invention is also useful for high throughput screening, e.g. combinatorial screening. The microfluidic device comprises a main channel and an inlet region in communication with the main channel at a droplet extrusion region. Droplets of solution containing the biological material are deposited into the main channel through the droplet extrusion region. A fluid different from and incompatible with the solution containing the biological material flows through the main channel so that the droplets containing the biological material do not diffuse or mix.Type: ApplicationFiled: October 8, 2007Publication date: February 5, 2009Applicant: California Institute of TechnologyInventors: Stephen R. Quake, Todd Thorsen
-
Publication number: 20090035837Abstract: An improved process for recovery of virus from allantoic fluid of virus-infected chick embryos. Virus associated with granular and fibrous debris in the allantoic fluid can be disassociated from the debris and recovered, thereby increasing viral yield. Dissociation can be achieved by subjecting the virus-debris complex to conditions of increased salt concentrations, e.g., 0.5 M or greater.Type: ApplicationFiled: September 17, 2007Publication date: February 5, 2009Applicant: MICROBIX BIOSYSTEMS INC.Inventors: Gregory V. Williams, Kenneth Hughes
-
Publication number: 20090029438Abstract: This invention relates to a composite material that comprises a support member that has a plurality of pores extending through the support member and, located in the pores of the support member, and filling the pores of the support member, a macroporous cross-linked gel. The invention also relates to a process for preparing the composite material described above, and to its use. The composite material is suitable, for example, for separation of substances, for example by filtration or adsorption, including chromatography, for use as a support in synthesis or for use as a support for cell growth.Type: ApplicationFiled: October 3, 2008Publication date: January 29, 2009Inventors: Ronald F. Childs, Carlos Filipe, Raja Ghosh, Alicja M. Mika, Jinsheng Zhou, Elena N. Komkova, Marcus Y. Kim, Tapan K. Dey
-
Publication number: 20090023197Abstract: The invention relates to a method for obtaining viruses from a liquid viral suspension, according to which: the viral suspension is subjected to density gradient ultracentrifugation, the ultracentrifugation is carried out continuously, and the density gradient is a discontinuous gradient comprising at least 2 steps.Type: ApplicationFiled: June 25, 2008Publication date: January 22, 2009Applicant: SANOFI PASTEUR SAInventors: Oliver Brass, Jean Marc Contzen, Alain Francon, Michel Tardy
-
Publication number: 20090017447Abstract: The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed.Type: ApplicationFiled: March 20, 2006Publication date: January 15, 2009Inventors: Marian Laderoute, Antonio Giulivi, Francisco Diaz-Mitoma, Louise Larocque
-
Publication number: 20090017523Abstract: Provided is a method for purifying a virus from a host cell, the method comprising: a) culturing host cells, b) infecting the host cells with a virus, c) treating the cell culture with nuclease, and d) lysing the host cells to provide a lysate comprising the virus. The virus may be recombinant adenovirus. Further provided are methods for purifying a recombinant virus expressing a heterologous protein capable of binding nucleic acid, comprising: a) culturing host cells, b) infecting the host cells with recombinant virus, c) lysing the host cells to provide a lysate comprising the recombinant virus, d) subjecting the recombinant virus to anion exchange chromatography and size exclusion chromatography, wherein the virus-containing mixture is buffer exchanged at least once with a solution comprising at least 2 M NaCl, or another salt providing an equivalent ionic strength.Type: ApplicationFiled: July 28, 2008Publication date: January 15, 2009Applicant: Crucell Holland B.V.Inventors: Miranda Weggeman, Emile Joannes Van Corven
-
Publication number: 20080317778Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost inoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: ApplicationFiled: August 28, 2008Publication date: December 25, 2008Inventors: Paul Chaplin, Paul Howley, Christine Meisinger-Henschel, Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20080318301Abstract: Methods for preparing cells and viruses such as poxviruses are provided herein.Type: ApplicationFiled: November 4, 2005Publication date: December 25, 2008Inventor: David Lau
-
Publication number: 20080311154Abstract: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity, dominant interference, or attenuation. Such viruses are formulated into therapeutic compositions to protect animals from diseases caused by influenza A viruses, and in particular, to protect horses from disease caused by equine influenza virus. The present invention also includes methods to protect animals from diseases caused by influenza A virus utilizing the claimed therapeutic compositions.Type: ApplicationFiled: May 7, 2008Publication date: December 18, 2008Inventors: Patricia W. Dowling, Julius S. Youngner
-
Publication number: 20080311143Abstract: Chimeric replicons of North American Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) containing the 5? sequence of an avirulent strain of PRRSV and a 3? sequence of a virulent strain of PRRSV are provided. Further provided is a method of producing attenuated PRRSV from the chimeric replicon. Also provided are compositions containing the replicon or attenuated virus. Vaccines and a method of vaccinating pigs against PRRSV are also provided.Type: ApplicationFiled: June 15, 2007Publication date: December 18, 2008Applicant: PROTATEK INTERNATIONAL, INC.Inventors: Xuexian Zhang, Shi-jun Ma
-
Patent number: 7465397Abstract: A process is provided for selectively removing protein aggregates from a protein solution in a normal flow (NFF) filtration process. Preferably, it relates to a process for selectively removing protein aggregates from a protein solution in a normal flow (NFF) filtration process and virus particles from a protein solution in a two-step filtration process. In a first step, a protein solution is filtered through one or more layers of adsorptive depth filters, charged or surface modified microporous membranes or a small bed of chromatography media in a normal flow filtration mode of operation, to produce a protein aggregate free stream. The aggregate free protein stream can then be filtered through one or more ultrafiltration membranes to retain virus particles at a retention level of at least 3 LRV and to allow passage therethrough of an aggregate free and virus free protein solution.Type: GrantFiled: July 19, 2006Date of Patent: December 16, 2008Assignee: Millipore CorporationInventors: Martin Siwak, Hong An, Jason R. Comier, Dana Kinzlmaier
-
Patent number: 7465574Abstract: The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes, tumor antigens, or to encode combinations of genes from different strains of RSV.Type: GrantFiled: March 11, 2005Date of Patent: December 16, 2008Assignee: MedImmune, LLCInventors: Hong Jin, Roderick Tang, Shengqiang Li, Martin Bryant
-
Patent number: 7459162Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 6, 2006Date of Patent: December 2, 2008Assignee: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20080293123Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.Type: ApplicationFiled: August 7, 2008Publication date: November 27, 2008Applicant: Schering CorporationInventors: Andreas Frei, Henry K.H. Kwan, Varda E. Sandweiss, Gary J. Vellekamp, Pui-Ho Yuen, Laureano L. Bondoc, JR., Frederick William Porter, IV, John Chu-Tay Tang, Peter Ihnat
-
Patent number: 7456008Abstract: A modified virus including one or more non-native polypeptides, and the use of such viruses in therapy, particularly in the treatment of tumours or other cancerous cells are disclosed. The polypeptides includes one or more framework moieties each containing one or more binding moieties, and is capable of being expressed in the cytoplasm and nucleus of a mammalian host cell in a conformation which is maintained in the absence of a ligand for the binding moieties. The conformation allows the binding moieties subsequently to bind with the ligand, and the polypeptide is capable of transport through the nuclear membrane, wherein the modified virus has an altered tropism conferred by the binding moieties.Type: GrantFiled: July 19, 2001Date of Patent: November 25, 2008Assignee: Got-A-Gene ABInventors: Leif Lindholm, Anna Karin Nord, Pierre Alain Boulanger
-
Publication number: 20080286307Abstract: The present invention provides a method for the production of a virus. The method includes providing a host cell that has been infected by the virus and cultivating the infected host cell at two different temperatures. The virus produced by the cultivation steps is subsequently collected. By using the dual temperature cultivation process, high titer and improved purity can be obtained.Type: ApplicationFiled: April 30, 2008Publication date: November 20, 2008Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt
-
Publication number: 20080286850Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.Type: ApplicationFiled: September 14, 2007Publication date: November 20, 2008Applicant: MEDIMMUNE VACCINES, INC.Inventors: Jonathan Liu, Richard Schwartz, Mark Thompson, Luis Jorge Camilo Maranga, Simon Sheng-Tsiung Hsu, Mridul Ghosh, Ajit Subramanian
-
Patent number: 7449324Abstract: The present invention provides an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. The invention also provides isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular the invention provides a mammalian MPV, subgroups and variants thereof. The invention relates to genomic nucleotide sequences of different isolates of mammalian metapneumoviruses, in particular human metapneumoviruses. The invention relates to the use of the sequence information of different isolates of mammalian metapneumoviruses for diagnostic and therapeutic methods. The present invention relates to nucleotide sequences encoding the genome of a metapneumovirus or a portion thereof, including both mammalian and avian metapneumovirus. The invention further encompasses chimeric or recombinant viruses encoded by said nucleotide sequences.Type: GrantFiled: February 21, 2003Date of Patent: November 11, 2008Assignees: ViroNovative BV, MedImmune, LLCInventors: Ronaldus Adrianus Maria Fouchier, Bernadetta Gerarda Van Den Hoogen, Albertus Dominicus Marcellinus Erasmus Osterhaus, Jan Cornelius De Jong, Jan Groen
-
Publication number: 20080274535Abstract: A rotating wall vessel is used as a culture vessel and bioreactor for the cultivation of hepatocytes in the form of spheroids to generate a culture with many properties of the intact liver. These properties include enzyme activity comparable to fresh cells and long-term maintenance of viability and cellular function for periods on the order of months. The cultures may be used to produce hepatocyte products, evaluate-metabolism of an agent, propagate Hepatitis C virus and test agents as inhibitors of this virus. Thus, the culture system disclosed herein makes long term functional cultivation of human hepatocytes feasible.Type: ApplicationFiled: March 31, 2008Publication date: November 6, 2008Applicant: In Vitro Technologies, Inc.Inventors: Paul M. Silber, Nancy L. Cowger, Ana P. Miller, Lanika A. Brown, Albert P. Li
-
Publication number: 20080274138Abstract: The present invention provides a method for purification of a virus or virus antigen comprising providing a virus preparation and centrifugation of said virus preparation in a gradient of a sugar established by the addition of two or more buffered sugar layers of different concentration. The method leads to higher yields and reduces unwanted aggregation of the virus or virus antigen by increasing the volume of the peak pool.Type: ApplicationFiled: April 30, 2008Publication date: November 6, 2008Applicants: BAXTER INTERNATIONAL INC., BAXTER HEALTHCARE S.A.Inventors: Manfred Reiter, Leopold Grillberger, Wolfgang Mundt, Artur Mitterer, Horst Schafhauser
-
Patent number: 7445924Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. The present invention relates to a method of virus amplification in primary cells which are cultivated in a serum free medium. Viruses produced by this method are advantageously free of any infectious agents comprised in animal sera.Type: GrantFiled: March 3, 2005Date of Patent: November 4, 2008Assignee: Bavarian Nordic A/SInventors: Paul Chaplin, Paul Howley, Christine Meisinger, Ingmar Rathe, Eva Felder, Karl Heller
-
Publication number: 20080260781Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.Type: ApplicationFiled: June 24, 2008Publication date: October 23, 2008Inventors: David S. Burt, David Hugh Jones, George H. Lowell, Gregory Leo White, Kirkor Torossian, Louis F. Fries, Martin Plante
-
Patent number: 7439058Abstract: Chimeric antigens derived from hepatitis B virus (HBV) and hepatitis C virus (HCV) are described which form virus-like particles when co-expressed with an excess of hepatitis B virus surface antigen (HBsAg). The chimeric antigens are fusion proteins containing an immunogenic peptide derived from an HCV protein coupled to the amino terminus of HBsAg. Also described are nucleic acid constructs and vectors for transfection of cells and expression of the chimeric antigens. The invention further provides methods for producing HBV/HCV virus-like particles containing the chimeric antigens, cell lines for producing the virus-like particles, combination vaccines containing the virus-like particles, and DNA vaccines that express the virus-like particles.Type: GrantFiled: November 17, 2003Date of Patent: October 21, 2008Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mark Selby, Edward Glazer, Michael Houghton
-
Publication number: 20080254067Abstract: The present invention relates to a commercial-scale process for the production of influenza virus or antigens for prophylactic, diagnostic, immunotherapeutic or therapeutic purposes. Particularly, the invention provides a Madin-Darby Canine Kidney (MDCK)-derived, cell line and a cell culture-based process for the production of an influenza vaccine and more particularly, a human vaccine comprising influenza types A and B.Type: ApplicationFiled: May 20, 2005Publication date: October 16, 2008Applicant: ID BIOMEDICAL CORPORATIONInventors: Pierre Trepanier, Robert Dugre, Tom Hassell
-
Publication number: 20080241906Abstract: The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.Type: ApplicationFiled: September 24, 2007Publication date: October 2, 2008Inventors: Michael Hallek, Anne Girod, Martin Ried, Christof Korner, Ulrich Moebius
-
Publication number: 20080241185Abstract: Imprinted polymeric materials that selectively bind to a template article. Various types of template articles may be targeted by the imprinted polymeric materials, including microorganisms (e.g., viruses or bacteria) or biologic macromolecules (e.g., proteins or DNA). The imprinted polymeric material may be formed by template-directed synthesis using monomer units that interact with the template article. The monomer units are used to form a polymer matrix around the template article. Subsequently, the template article is removed from the polymer matrix. Also disclosed are imprinted polymeric materials comprising a cross-linked polymer matrix, which comprises a polyampholyte polymer. The polymer matrix has a binding cavity capable of selectively binding to a template article. Also disclosed are various uses for such imprinted polymeric materials.Type: ApplicationFiled: March 14, 2008Publication date: October 2, 2008Applicant: University of Maryland, College ParkInventors: Peter KOFINAS, Daniel JANIAK
-
Patent number: 7429485Abstract: A simple and efficient method of producing mammalian reovirus is developed using HEK 293 cells. The method provides for fast production of reovirus in high yield. Furthermore, this method provides for a simpler purification procedure of the produced reovirus.Type: GrantFiled: March 27, 2006Date of Patent: September 30, 2008Assignee: Oncolytics Biotech Inc.Inventors: Bradley G. Thompson, Mathew C. Coffey
-
Publication number: 20080226594Abstract: The present invention relates to the use of interferon in the in vitro cultivation of animal circular ssDNA virus such as Porcine Circovirus 2 or human TT virus in an animal cell line. Increased titres of animal circular ssDNA virus are obtained by one or more of the following conditions: addition of interferons or agents which ensure the production of endogenous interferons by said cell line, reduction of endosomal-lysosomal system acidification, and cholesterol depletion.Type: ApplicationFiled: November 23, 2007Publication date: September 18, 2008Inventors: Hans NAUWYNCK, Gerald MISINZO, Sven ARNOUTS
-
Patent number: 7425437Abstract: The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.Type: GrantFiled: April 20, 2005Date of Patent: September 16, 2008Assignee: Crucell Holland B.V.Inventors: Alphonsus G. C. M. UytdeHaag, Govert Johan Schouten, Jaap Goudsmit
-
Publication number: 20080213304Abstract: Embodiments of the present invention generally relate to novel methods for the treatment and/or prevention of neurological symptoms caused by an avian reovirus, enteric reovirus strain (ERS), and associated characteristics. Other embodiments generally comprise and immunogenic composition or vaccine comprising an ERS for the treatment and/or prevention of neurological symptoms.Type: ApplicationFiled: October 9, 2003Publication date: September 4, 2008Applicant: INTERVET INTERNATIONAL B.V.Inventors: Saskia van de Zande, Rudolf George Hein, Donald Eugene Roessler, Gwenllyan F. Slacum, Karen L. Jensen, Phyllis A. Lynch
-
Patent number: 7419817Abstract: The present invention provides methods of purifying adeno-associated virus (AAV) particles. These AAV particles include AAV2, AAV4 and AAV5 particles. The present invention also provides AAV particles purified by the methods of the present invention.Type: GrantFiled: May 17, 2002Date of Patent: September 2, 2008Assignee: The United States of America as represented by the Secretary Department of Health and Human Services, NIH.Inventors: John A. Chiorini, Nikola A. Kaludov
-
Publication number: 20080206741Abstract: The present invention relates to a virus recovery medium and a viral diagnostic kit comprising the same. The virus recovery medium is supplemented with a hormone and an enzyme. The hormone is preferably a glucocorticoid hormone, more preferably dexamethasone. The enzyme is preferably a protease, more preferably trypsin.Type: ApplicationFiled: January 13, 2006Publication date: August 28, 2008Inventor: Robert Alexander
-
Publication number: 20080206812Abstract: This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterologous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus.Type: ApplicationFiled: August 8, 2007Publication date: August 28, 2008Inventors: Edward M. Atkinson, Victor P. Fung, Perry C. Wilkins, Ryan K. Takeya, Thomas C. Reynolds, Ian L. Aranha
-
Patent number: 7413889Abstract: The present invention relates to foreign peptide sequences fused to recombinant plant viral structural proteins and a method of their production. Fusion proteins are economically synthesized in plants at high levels by biologically contained tobamoviruses. The fusion proteins of the invention have are useful as antigens for inducing the production of antibodies having desired binding properties, e.g., protective antibodies, or for use as vaccine antigens for the induction of protective immunity against the parvovirus. Feline parvovirus epitopes were fused to the N-terminus of the TMV coat protein, expressed in Nicotiana plants, extracted, purified, characterized and administered to animals, resulting in protective immunity.Type: GrantFiled: February 4, 2002Date of Patent: August 19, 2008Assignee: Kentucky Bioprocessing, LLCInventors: Gregory P. Pogue, John A. Lindbo, Michael J. McCulloch, Jonathan E. Lawrence, Cynthia S. Gross, Stephen J. Garger
-
Publication number: 20080194002Abstract: A composition is disclosed comprising virus in a formulation comprising a polyhydroxy hydrocarbon buffered to maintain a pH in a range from about 7 to about 8.5 at a temperature in the range from about 2° C. to 27° C. Methods for concentrating and purifying virus preparations are also disclosed.Type: ApplicationFiled: April 14, 2008Publication date: August 14, 2008Applicant: Canji, Inc.Inventors: Andreas Frei, Henry K.H. Kwan, Varda E. Sandweiss, Gary J. Vellekamp, Pui-Ho Yuen, Laureano L. Bondoc, Frederick William Porter, John Chu-Tay Tang, Peter Ihnat
-
Publication number: 20080187546Abstract: The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.Type: ApplicationFiled: December 14, 2007Publication date: August 7, 2008Inventors: Terri L. Wasmoen, Peng Gao, Bradley Allen Eddy, Omar Yousif Abdelmagid